Top

Gepubliceerd in:

20-11-2024

Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial

Auteurs: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, Jean-Paul Bahary, Peter Vavassis, Sylvie Vass, Boris Bahoric, Robert Archambault, François Vincent, Redouane Bettahar, Luis Souhami

Gepubliceerd in: Quality of Life Research | Uitgave 3/2025

Abstract

Purpose

The aim was to compare quality of life (QoL) of patients with testosterone recovery (TR) to patients without TR after the completion of either 18- or 36-month androgen deprivation therapy (ADT) for prostate cancer.

Methods

From a Phase III trial, we selected all 630 randomised patients with testosterone measured at baseline (during screening, before randomisation) and follow-up and who completed baseline, 6-month and, at least, one further QoL questionnaire in follow-up (EORTC 30 - PR25). We estimated means and standard deviation of items and scales for each group at each time point. We analyzed items and scales scores with general linear model with repeated measures to evaluate changes between patients with or without TR to a normal level. p-values were adjusted for multiple comparisons with Benjamini-Hochberg’s false discovery rate procedure (p_adj). A p_adj < 0.05 was considered significant and mean differences of 10 points or more considered clinically relevant.

Results

494 patients retained for analysis (median follow-up 16.2 years). A significantly higher number of patients (177/314 vs 79/180, p = 0.008) recovered a normal testosterone level in a significantly shorter time [median (IQR): 3.06 (2.55–3.65) vs 5.00 years (4.5–5.96), p < 0.001] in the 18- vs the 36-month cohort. Patients with TR had a significantly better QoL: 37/55 items and 14/21 scales (p_adj<0.05) in the 18-month and 25/55 items and 13/21 scales in the 36-month cohort. Moreover, 9 items and one scale reached clinical relevance in the 18-month cohort and 7 items and one scale in the 36-month cohort.

Conclusions

TR is associated with significant regaining in QoL. A faster and significantly higher TR is seen in the shorter ADT schedule.

vorige artikel Factors that impact the implementation of patient reported outcomes in routine clinical care for peripheral artery disease from the patient perspective

volgende artikel Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study

Alleen toegankelijk voor geautoriseerde gebruikers

AstraZeneca Pharmaceuticals funded PCS IV study but was not involved in any step of the trial design or manuscript preparation.

Bolla, M., Van Tienhoven, G., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Billiet, I., Torecilla, J. L., Pfeffer, R., Cutajar, C. L., Van der Kwast, T., & Collette, L. (2010). External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncology, 11(11), 1066–1073. https://doi.org/10.1016/S1470-2045(10)70223-0CrossRefPubMed

Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. (2005). Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85 – 31. International Journal of Radiation Oncology Biology Physics, 61(5), 1285–1290. https://doi.org/10.1016/j.ijrobp.2004.08.047CrossRefPubMed

Warde, P., Mason, M., Ding, K., Kirkbride, P., Brundage, M., Cowan, R., Gospodarowicz, M., Sanders, K., Kostashuk, E., Swanson, G., Barber, J., Hiltz, A., Parmar, M. K., Sathya, J., Anderson, J., Hayter, C., Hetherington, J., Sydes, M. R., & Parulekar, W. (2011). Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet (London England), 378(9809), 2104–2111. https://doi.org/10.1016/S0140-6736(11)61095-7. & NCIC CTG PR.3/MRC UK PR07 investigatorsCrossRefPubMed

Jones, J. M., Kohli, M., & Loprinzi, C. L. (2012). Androgen deprivation therapy-associated vasomotor symptoms. Asian Journal of Andrology, 14(2), 193–197. https://doi.org/10.1038/aja.2011.101CrossRefPubMedPubMedCentral

Stone, P., Hardy, J., Huddart, R., A’Hern, R., & Richards, M. (2000). Fatigue in patients with prostate cancer receiving hormone therapy. European Journal of Cancer (Oxford England: 1990), 36(9), 1134–1141. https://doi.org/10.1016/s0959-8049(00)00084-8CrossRefPubMed

Strum, S. B., McDermed, J. E., Scholz, M. C., Johnson, H., & Tisman, G. (1997). Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. British Journal of Urology, 79(6), 933–941. https://doi.org/10.1046/j.1464-410x.1997.00234.xCrossRefPubMed

Smith, M. R., Saad, F., Egerdie, B., Sieber, P. R., Tammela, T. L., Ke, C., Leder, B. Z., & Goessl, C. (2012). Sarcopenia during androgen-deprivation therapy for prostate cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30(26), 3271–3276. https://doi.org/10.1200/JCO.2011.38.8850CrossRefPubMed

Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. The Journal of Clinical Endocrinology and Metabolism, 87(2), 599–603. https://doi.org/10.1210/jcem.87.2.8299CrossRefPubMed

Nead, K. T., Sinha, S., Yang, D. D., & Nguyen, P. L. (2017). Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urologic Oncology, 35(11), 664e1–664e9. https://doi.org/10.1016/j.urolonc.2017.07.016CrossRef

10.

Dinh, K. T., Yang, D. D., Nead, K. T., Reznor, G., Trinh, Q. D., & Nguyen, P. L. (2017). Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer. International Journal of Urology: Official Journal of the Japanese Urological Association, 24(10), 743–748. https://doi.org/10.1111/iju.13409CrossRefPubMed

11.

Braga-Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J., & Basaria, S. (2006). Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 24(24), 3979–3983. https://doi.org/10.1200/JCO.2006.05.9741CrossRefPubMed

12.

Haliloglu, A., Baltaci, S., & Yaman, O. (2007). Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer. The Journal of Urology, 177(1), 128–130. https://doi.org/10.1016/j.juro.2006.08.113CrossRefPubMed

13.

Gay, H. A., Sanda, M. G., Liu, J., Wu, N., Hamstra, D. A., Wei, J. T., Dunn, R. L., Klein, E. A., Sandler, H. M., Saigal, C. S., Litwin, M. S., Kuban, D. A., Hembroff, L., Regan, M. M., Chang, P., Michalski, J. M., & Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium. (2017). External Beam Radiation Therapy or Brachytherapy with or without short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, prospective study of quality of life. International Journal of Radiation Oncology Biology Physics, 98(2), 304–317. https://doi.org/10.1016/j.ijrobp.2017.02.019CrossRefPubMed

14.

Fode, M., & Sønksen, J. (2014). Sexual function in Elderly men receiving androgen deprivation therapy (ADT). Sexual Medicine Reviews, 2(1), 36–46. https://doi.org/10.1002/smrj.17CrossRefPubMed

15.

Okwuosa, T. M., Morgans, A., Rhee, J. W., Reding, K. W., Maliski, S., Plana, J. C., Volgman, A. S., Moseley, K. F., Porter, C. B., Ismail-Khan, R., & American Heart Association Cardio-Oncology Subcommittee of the Council on Clinical Cardiology and the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular Radiology and Intervention. (2021). Impact of Hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the Cardiovascular System: Effects and modifications: A Scientific Statement from the American Heart Association. Circulation Genomic and Precision Medicine, 14(3), e000082. https://doi.org/10.1161/HCG.0000000000000082CrossRefPubMed

16.

Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., & Pashos, C. L. (2005). Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23(31), 7897–7903. https://doi.org/10.1200/JCO.2004.00.6908CrossRefPubMed

17.

Krupski, T. L., Smith, M. R., Lee, W. C., Pashos, C. L., Brandman, J., Wang, Q., Botteman, M., & Litwin, M. S. (2004). Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer, 101(3), 541–549. https://doi.org/10.1002/cncr.20388CrossRefPubMed

18.

Shahinian, V. B., Kuo, Y. F., Freeman, J. L., & Goodwin, J. S. (2005). Risk of fracture after androgen deprivation for prostate cancer. The New England Journal of Medicine, 352(2), 154–164. https://doi.org/10.1056/NEJMoa041943CrossRefPubMed

19.

Wadhwa, V. K., Weston, R., Mistry, R., & Parr, N. J. (2009). Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU International, 104(6), 800–805. https://doi.org/10.1111/j.1464-410X.2009.08483.xCrossRefPubMed

20.

Nguyen, P. L., Alibhai, S. M., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015). Adverse effects of androgen deprivation therapy and strategies to mitigate them. European Urology, 67(5), 825–836. https://doi.org/10.1016/j.eururo.2014.07.010CrossRefPubMed

21.

Nabid, A., Carrier, N., Vigneault, E., Martin, A. G., Bahary, J. P., Van Nguyen, T., Vavassis, P., Vass, S., Brassard, M. A., Bahoric, B., Archambault, R., Vincent, F., Bettahar, R., Duclos, M., Wilke, D., & Souhami, L. (2024). Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 195, 110256. https://doi.org/10.1016/j.radonc.2024.110256CrossRefPubMed

22.

Nabid, A., Carrier, N., Martin, A. G., Bahary, J. P., Lemaire, C., Vass, S., Bahoric, B., Archambault, R., Vincent, F., Bettahar, R., Duclos, M., Garant, M. P., & Souhami, L. (2018). Duration of Androgen Deprivation Therapy in High-risk prostate Cancer: A Randomized Phase III Trial. European Urology, 74(4), 432–441. https://doi.org/10.1016/j.eururo.2018.06.018CrossRefPubMed

23.

Roach, M. 3rd, Hanks, G., Thames, H. Jr, Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006). Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology, Biology, Physics, 65(4), 965–974. https://doi.org/10.1016/j.ijrobp.2006.04.029

24.

Nolte, S., Liegl, G., Petersen, M. A., Aaronson, N. K., Costantini, A., Fayers, P. M., Groenvold, M., Holzner, B., Johnson, C. D., Kemmler, G., Tomaszewski, K. A., Waldmann, A., Young, T. E., Rose, M., & EORTC Quality of Life Group. (2019). & General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. European Journal of Cancer (Oxford, England: 1990), 107, 153–163. https://doi.org/10.1016/j.ejca.2018.11.024

25.

Cocks, K., Wells, J. R., Johnson, C., Schmidt, H., Koller, M., Oerlemans, S., Velikova, G., Pinto, M., Tomaszewski, K. A., Aaronson, N. K., Exall, E., Finbow, C., Fitzsimmons, D., Grant, L., Groenvold, M., Tolley, C., Wheelwright, S., & Bottomley, A. (1990). & European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (2023). Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. European Journal of Cancer (Oxford, England: 178, 128–138. https://doi.org/10.1016/j.ejca.2022.10.026

26.

van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S., Kynaston, H., Gontero, P., Thalmann, G., Akdas, A., D’Haese, S., & Aaronson, N. K. (2008). An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer (Oxford England: 1990), 44(16), 2418–2424. https://doi.org/10.1016/j.ejca.2008.07.030CrossRefPubMed

27.

Ratti, M. M., Gandaglia, G., Alleva, E., Leardini, L., Sisca, E. S., Derevianko, A.,Furnari, F., Mazzoleni Ferracini, S., Beyer, K., Moss, C., Pellegrino, F., Sorce,G., Barletta, F., Scuderi, S., Omar, M. I., MacLennan, S., Williamson, P. R., Zong,J., MacLennan, S. J., Mottet, N., … PIONEER Consortium (2022). Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review.European Urology Oncology, 5(2), 153–163. https://doi.org/10.1016/j.euo.2021.10.004.

28.

Fayers, P., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001). EORTC QLQ-C30. Scoring Manual (3rd ed.). European Organisation for Research and Treatment of Cancer.

29.

Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 16(1), 139–144. https://doi.org/10.1200/JCO.1998.16.1.139CrossRefPubMed

30.

West, H. J., & Jin, J. O. (2015). JAMA Oncology Patient Page. Performance status in patients with Cancer. JAMA Oncology, 1(7), 998. https://doi.org/10.1001/jamaoncol.2015.3113CrossRefPubMed

31.

Nam, W., Choi, S. Y., Yoo, S. J., Ryu, J., Lee, J., Kyung, Y. S., Han, J. H., You, D., Jeong, I. G., Hong, J. H., Ahn, H., & Kim, C. S. (2018). Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer. Investigative and Clinical Urology, 59(1), 18–24. https://doi.org/10.4111/icu.2018.59.1.18CrossRefPubMed

32.

Planas, J., Celma, A., Placer, J., Cuadras, M., Regis, L., Gasanz, C., Trilla, E., Salvador, C., Lorente, D., & Morote, J. (2016). Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer. Scandinavian Journal of Urology, 50(6), 425–428. https://doi.org/10.1080/21681805.2016.1227876CrossRefPubMed

33.

Nascimento, B., Miranda, E. P., Jenkins, L. C., Benfante, N., Schofield, E. A., & Mulhall, J. P. (2019). Testosterone recovery profiles after Cessation of Androgen deprivation therapy for prostate Cancer. The Journal of Sexual Medicine, 16(6), 872–879. https://doi.org/10.1016/j.jsxm.2019.03.273CrossRefPubMedPubMedCentral

34.

Yoon, F. H., Gardner, S. L., Danjoux, C., Morton, G., Cheung, P., & Choo, R. (2008). Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. The Journal of Urology, 180(4), 1438–1444. https://doi.org/10.1016/j.juro.2008.06.029CrossRefPubMed

35.

Potosky, A. L., Knopf, K., Clegg, L. X., Albertsen, P. C., Stanford, J. L., Hamilton, A. S., Gilliland, F. D., Eley, J. W., Stephenson, R. A., & Hoffman, R. M. (2001). Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate Cancer outcomes Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 19(17), 3750–3757. https://doi.org/10.1200/JCO.2001.19.17.3750CrossRefPubMed

36.

Dacal, K., Sereika, S. M., & Greenspan, S. L. (2006). Quality of life in prostate cancer patients taking androgen deprivation therapy. Journal of the American Geriatrics Society, 54(1), 85–90. https://doi.org/10.1111/j.1532-5415.2005.00567.xCrossRefPubMed

37.

Gudenkauf, L. M., Gray, S., Gonzalez, B. D., Sachdeva, A., & Autio, K. (2024). Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 44(3), e433126. https://doi.org/10.1200/EDBK_433126

38.

Eton, D. T., & Lepore, S. J. (2002). Prostate cancer and health-related quality of life: A review of the literature. Psycho-Oncology, 11(4), 307–326. https://doi.org/10.1002/pon.572CrossRefPubMedPubMedCentral

39.

Pinkawa, M., Fischedick, K., Gagel, B., Piroth, M. D., Asadpour, B., Klotz, J., Borchers, H., Jakse, G., & Eble, M. J. (2009). Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: Evaluation before a curative treatment. Bmc Cancer, 9, 296. https://doi.org/10.1186/1471-2407-9-296CrossRefPubMedPubMedCentral

40.

Potosky, A. L., Reeve, B. B., Clegg, L. X., Hoffman, R. M., Stephenson, R. A., Albertsen, P. C., Gilliland, F. D., & Stanford, J. L. (2002). Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. Journal of the National Cancer Institute, 94(6), 430–437. https://doi.org/10.1093/jnci/94.6.430CrossRefPubMed

41.

Bruner, D. W., Hunt, D., Michalski, J. M., Bosch, W. R., Galvin, J. M., Amin, M., Xiao, C., Bahary, J. P., Patel, M., Chafe, S., Rodrigues, G., Lau, H., Duclos, M., Baikadi, M., Deshmukh, S., & Sandler, H. M. (2015). Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer, 121(14), 2422–2430. https://doi.org/10.1002/cncr.29362CrossRefPubMed

Titel: Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial
Auteurs: Abdenour Nabid
Nathalie Carrier
André-Guy Martin
Jean-Paul Bahary
Peter Vavassis
Sylvie Vass
Boris Bahoric
Robert Archambault
François Vincent
Redouane Bettahar
Luis Souhami
Publicatiedatum: 20-11-2024
Uitgeverij: Springer New York
Gepubliceerd in: Quality of Life Research / Uitgave 3/2025
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-024-03843-5

Andere artikelen Uitgave 3/2025

Trajectories of dyadic quality of life in young to middle-aged stroke couples: a longitudinal study

Association between cardiovascular health and perceived quality of life in ethnically diverse adults: insights from the Community of Mine study using the American Heart Association’s Life’s Simple 7

Open Access

Patient-reported health status in TTR amyloidosis: which yardstick to use?

Letter to the Editor

Understanding diagnostic delays and health outcomes for inflammatory bowel disease: a mixed-methods study of patients’ perspectives

Health utilities used in oncology cost-utility analyses: a registry-based analysis

Quality of life dimensions in people living with mental disorders: moving beyond global scores

Editorial

Bohn Stafleu van Loghum

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

Registreer

Login

Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial

Abstract

Purpose

Methods

Results

Conclusions

Andere artikelen Uitgave 3/2025

Trajectories of dyadic quality of life in young to middle-aged stroke couples: a longitudinal study

Association between cardiovascular health and perceived quality of life in ethnically diverse adults: insights from the Community of Mine study using the American Heart Association’s Life’s Simple 7

Patient-reported health status in TTR amyloidosis: which yardstick to use?

Understanding diagnostic delays and health outcomes for inflammatory bowel disease: a mixed-methods study of patients’ perspectives

Health utilities used in oncology cost-utility analyses: a registry-based analysis

Quality of life dimensions in people living with mental disorders: moving beyond global scores

Bohn Stafleu van Loghum

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

Registreer

Login

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusions

Log in om toegang te krijgen

Trajectories of dyadic quality of life in young to middle-aged stroke couples: a longitudinal study

Association between cardiovascular health and perceived quality of life in ethnically diverse adults: insights from the Community of Mine study using the American Heart Association’s Life’s Simple 7

Patient-reported health status in TTR amyloidosis: which yardstick to use?

Understanding diagnostic delays and health outcomes for inflammatory bowel disease: a mixed-methods study of patients’ perspectives

Health utilities used in oncology cost-utility analyses: a registry-based analysis

Quality of life dimensions in people living with mental disorders: moving beyond global scores